Healthy Extracts Sees First Half 2026 Net Revenue Up More Than 93% to Record $3.6 Million+

Healthy Extracts (OTCQB: HYEX) expects Q2 2026 net revenue to exceed a record $2.0M, up more than 112% sequentially and 129% year-over-year. The outlook is described as being enhanced by the acquisition of Sommer Ray’s Imaraïs Beauty and resulting major national B2B customer wins. The company also expects record revenue for both Q2 and the first half ended June 30, 2026.

Analysis

This is less a "growth stock" signal than a proof-of-distribution event: at this revenue base, the equity rerates only if management can show that new B2B wins convert into repeat orders, stable gross margin, and positive operating cash flow. A celebrity-branded acquisition can help top-line optics, but for microcaps it often comes with lower-quality revenue: promotional spend, SKU complexity, and working-capital drag that can outpace near-term EBITDA.

The second-order winner, if this is real, is the broader gummy/contract-manufacturing ecosystem: packaging, flavoring, and co-manufacturing capacity should see spillover demand as smaller brands try to scale into national retail. The loser is any competitor dependent on discretionary shelf resets and one-off promotions; if these wins are recurring, it implies a small but meaningful share shift away from private-label and regional nutraceutical brands. The key question is whether these are purchase orders or durable programs.

The consensus is probably over-discounting execution risk because the revenue inflection is easy to see but the cash conversion is not. In the next 1-3 months, the 10-Q is the real catalyst: gross margin, receivables growth, inventory turns, and share count will tell us whether growth was financed or earned. Over 6-18 months, if repeat B2B demand persists, the stock can move from promo multiple to a more defensible revenue-multiple framework; if not, this fades back to dilution and integration risk.

Key Decisions for Investors

• Do not chase the print pre-filing; wait for the Q2 10-Q and require confirmation of margin stability and no material working-capital blowout before taking any long exposure.
• If the filing shows gross margin holding and operating cash flow improving, initiate a small tactical long in HYEX for 1-3 months with a 2:1 upside/downside setup; the rerating comes from credibility, not absolute revenue size.
• Fade any post-release spike if receivables or inventory grow faster than sales or if share count has expanded; that would indicate revenue quality is weak and the move is likely to mean-revert within weeks.
• Set an alert on repeat-order language and customer concentration in the next filing; a single large customer can make the headline growth non-recurring, which would cap the valuation multiple.